<DOC>
	<DOCNO>NCT01328054</DOCNO>
	<brief_summary>This study estimate effect lapatinib cardiac repolarization ( QTc interval duration ) subject advanced solid tumor . The study treatment period occur five day End Study visit conduct Day 8 ( later 3 day beyond Day 8 ) . Subjects receive placebo mimic lapatinib 2 day three separate dos give 12 hour apart ( 8 tablets/dose ) lapatinib ( 2000mg ) 2 day three separate dos give 12 hour apart ( 8 tablets/dose ) . Subjects know receive placebo vs. lapatinib . Digital 12-lead ECG recording extract continuous ECG recording obtain via Holter monitor measure QTc interval duration . Triplicate ECG measurement QTc interval take pre-specified time Day 1 ( Baseline ) pre-dose 24 hour third dose placebo lapatinib Study Days 2 4 . Pharmacokinetic sample occur immediately follow pre-specified QTc measurement subject dose placebo lapatinib . Subjects complete participation study , eligible , offer option continue treatment lapatinib , either alone combination oncology drug pre-selected anticancer regimen , continuation protocol , EGF111767 .</brief_summary>
	<brief_title>A Study Cancer Patients Evaluate Effect Lapatinib QTc Interval</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis : Metastatic breast cancer overexpresses ErbB2 OR Recurrent , advance , metastatic solid tumor malignancy ( include breast cancer overexpress ErbB2 ) refractory standard therapy , approve therapy , lapatinib combination one permit anticancer regimen specify continuation study EGF111767 may provide clinical benefit . A female subject must nonchildbearing potential willing use acceptable contraception . A male subject female partner childbearing potential must agree use acceptable contraception . Is able swallow retain oral medication uncontrolled emesis . ECOG performance status 0 1 . Adequate bone marrow function : ANC ( absolute neutrophil count ) &gt; /=1.5 x 10^9/L , Hemoglobin &gt; /=9 g/dL , Platelets &gt; /=75 x 10^9/L . Albumin &gt; /=3 g/dL . Serum bilirubin &lt; /=1.5 x ULN . AST ALT &lt; /=3 x ULN . Serum Creatinine &lt; /=1.5 mg/dL Calculated Creatinine Clearance &gt; /= 50 mL/min . Serum potassium magnesium level within normal limit . Has LVEF within normal institutional range ( &gt; /=50 % ) . Any follow ECG finding : QTcF interval &gt; 480 msec , PR interval &gt; 240 msec &lt; /=110 msec , Bradycardia define sinus rate &lt; 50 beat per minute . Cardiac conduction abnormality denote follow : Evidence seconddegree ( type II ) thirddegree atrioventricular block , Evidence ventricular preexcitation , Electrocardiographic evidence complete leave bundle branch block ( LBBB ) , Intraventricular conduction delay QRS duration &gt; 120 msec , Atrial fibrillation , Presence cardiac pacemaker . History one follow cardiovascular condition within past 6 month : Class III IV congestive heart failure define New York Heart Association ( NYHA ) , cardiac angioplasty stenting , myocardial infarction , unstable angina , symptomatic peripheral vascular disease clinically significant cardiac disease . Personal history longQT syndrome . Is pregnant lactating . Has malabsorption syndrome , undergone resection bypass distal stomach pylorus , small bowel . Has acute currently active/requiring antiviral therapy hepatic biliary disease ( exception subject Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) . Has evidence symptomatic uncontrolled brain metastasis leptomeningeal disease . Subjects brain metastasis treat surgery and/or radiotherapy eligible neurologically stable require steroid anticonvulsant least 28 day prior first dose study drug . Has know immediate delay hypersensitivity reaction idiosyncratic reaction drug chemically relate investigational product . Has receive anticancer therapy ( include chemotherapy , radiation therapy , immunotherapy , biologic therapy , investigational therapy , surgery , hormonal therapy ) within 14 day prior first dose study medication . Is receive prohibit medication consume food beverage within timeframe indicate prohibited medication list protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>cardiac repolarization</keyword>
	<keyword>Holter monitor</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>GW572016</keyword>
	<keyword>lapatinib</keyword>
	<keyword>QTc interval</keyword>
	<keyword>safety</keyword>
	<keyword>ECG</keyword>
</DOC>